Medivir presenting at the National Swedish Hepatitis Meeting - Clinical update on TMC435 HCV-protease inhibitor -

Medivir presenting at the National Swedish Hepatitis Meeting - Clinical
update on TMC435 HCV-protease inhibitor -

Medivir AB (OMX: MVIR), the biopharmaceutical company focused on
infectious diseases caused by viruses, will today present a clinical
update on its key drug, TMC435, a potential blockbuster therapy against
Hepatitis C which is partnered with Tibotec, at the National Swedish
Hepatitis Meeting. 

Medivir's CSO, Prof Bertil Samuelsson, will give a presentation entitled
'Clinical update of TMC435 HCV-protease inhibitor' at 12:30 CEST on 9
September 2010 at the Nordic Sea Hotel in Stockholm. A copy of the
presentation will be available on Medivir's website
(www.medivir.se (http://www.medivir.se/)) after the meeting. 

For more information, please contact:

Medivir Rein Piir, CFO & VP Investor Relations                          
                             Office: +46 8 546 831 23 Mobile:
+46 708 537 292 
M:Communications Mary-Jane Elliott / Emma Thompson
Medivir@mcomgroup.com (Medivir@mcomgroup.com)        +44(0)20 7920 2345

About Medivir
Medivir is an established biopharmaceutical company focused on the
development of high-value treatments mainly in infectious diseases. 
Medivir has world class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product, an innovative treatment for cold
sores.

Xerese™/Xerclear™ is a treatment for cold sores, which has been approved
in both the US and Europe. It is partnered with GSK to be sold OTC in
Europe and Russia and by Meda in North America. Medivir have retained
the Rx rights for Xerclear™ in Sweden and Finland. 

Medivir's key pipeline asset, TMC435, a protease inhibitor, is in Phase
IIb clinical development for Hepatitis C and is partnered with Tibotec. 

For more information on Medivir, please see the company website:
www.medivir.se